Orthofix International (OFIX) Stock Forecast & Price Target

Orthofix Medical Inc. demonstrated robust financial performance driven by strong growth across its primary segments, with the Global Spine segment achieving a notable 10% increase in revenue. The U.S. spinal fixation sector specifically contributed to this growth, recording a 5% revenue uptick alongside impressive advances in lateral, minimally invasive lumbar, and cervical procedures. Furthermore, the company anticipates sustained growth in the bone growth therapies (BGT) business, which is expected to outpace market expectations of 2% to 3%, highlighting favorable long-term prospects for Orthofix Medical.

Orthofix Medical Inc. has issued guidance for fiscal year 2026 that falls short of expectations, along with a delay in its long-term adjusted EBITDA margin target to 2028, indicating potential operational challenges. Despite reporting a fourth-quarter revenue of $219.9 million that surpassed estimates, the revenue from spinal implants, biologics, and enabling technologies totaled $113.6 million, which was below anticipated figures. Additionally, the company's GAAP selling, general, and administrative expenses were notably high at 72.0% of revenue, raising concerns about cost management moving forward.